Image

Middle East and Africa Neuroendocrine Tumors Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Published Report
  • May 2021
  • MEA
  • 350 Pages
  • No of Tables: 162
  • No of Figures: 48

Middle East and Africa Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI), Grade (Grade 1 {Low-Grade Tumor}, Grade 2 {Intermediate-Grade Tumor}, Grade 3 {High-Grade Tumor}), Type (Diagnosis and Treatment), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Radiation Centres, Home Healthcare and Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait & Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Middle East and Africa Neuroendocrine Tumors Market

Market Analysis and Insights: Middle East and Africa Neuroendocrine Tumors Market

Neuroendocrine tumors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.3% in the forecast period of 2021 to 2028 and is expected to reach USD 174.12 million by 2028. Strategic initiatives by market players and advent of mass vaccination programmes for neuroendocrine tumors are likely to be the major drivers which propelled the demand of the market in the forecast period.

The intiation of tumor takes place when the DNA of healthy cells is damaged which causes the cells to change and grow in an uncontrolled manner, hence forming an aggregated mass of cells. A tumor can be cancerous and benign. A malignant cancerous tumor grows and spreads to other parts of the body if it is not found early and treated. A benign tumor can grow but will not spread. A benign tumor usually can be removed with use of minimally invasive surgery without it causing much harm. A neuroendocrine tumor (NET) begins in the specialized cells of the body’s neuroendocrine system. These cells have common traits of both hormone-producing endocrine cells and nerve cells. They are found throughout the body’s organs and are responsible to control many of the body’s functions. All NETs are considered as malignant tumors. Most of the NETs take many years to develop and grow slowly.

However, the factors such as side effects associated with treatments, unmet needs and access to medical resources in several regions, high cost of diagnosis are hampering the growth of the neuroendocrine tumors market. On the other hand, the upcoming targeted treatments and rising partnerships and collaborations among the market players acts as an opportunity for the growth of the neuroendocrine tumors market. The lack of reimbursement policies and the stringent government regulations for neuroendocrine tumors drugs development are the challenges faced in the neuroendocrine tumors market.

The neuroendocrine tumors market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Neuroendocrine Tumors Market

Neuroendocrine Tumors Market Scope and Market Size

Neuroendocrine tumors market is segmented on the basis of classification, site, grade, type, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of classification, the neuroendocrine tumors market is segmented into functional net and non-functional net. In 2021 the non-functional net segment is dominating the neuroendocrine tumors market due to ease of identification and diagnosis and use of novel diagnostic method to remove the non-functional net.
  • On the basis of site, the neuroendocrine tumors market is segmented into lung, pancreas and gastrointestinal tract (GI). In 2021 the gastrointestinal tract (GI) segment is dominating the neuroendocrine tumors market due to the increased prevalence of gastric cancer and presence of strong product pipeline are predicted to dominate the market.
  • On the basis of grade, the neuroendocrine tumors market is segmented into grade 1 (low-grade tumor), grade 2 (intermediate-grade tumor) and grade 3 (high-grade tumor). In 2021, the grade 2 (intermediate-grade tumor) segment is dominating the neuroendocrine tumors market since it can be easily cured by therapeutic treatments and rise in grade 2 (intermediate-grade tumor) cases are predicted to dominate the market.
  • On the basis of type, the neuroendocrine tumors market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the neuroendocrine tumors market due to the increased incidence of pancreatic cancer tumor and increased adoption of automated point of care diagnosis in the market.
  • On the basis of route of administration, the neuroendocrine tumors market is segmented into oral and parenteral. In 2021, oral segment is expected to dominate the neuroendocrine tumors market due to availability of medication in oral form, greater patient’s compliance and ease of absorption.
  • On the basis of end user, the neuroendocrine tumors market is segmented into hospitals, specialty clinics, radiation centers, home healthcare and others. In 2021, hospitals segment is expected to dominate the neuroendocrine tumors market due to the availability of diagnostics machines to detect neuroendocrine tumor with the availability of healthcare policies.
  • On the basis of distribution channel, the neuroendocrine tumors market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment is expected to dominate the neuroendocrine tumors market due to rise of suppliers in the market.

Neuroendocrine Tumors Market Country Level Analysis

The neuroendocrine tumors market is analysed and market size information is provided classification, site, grade, type, route of administration, end user and distribution channel as referenced above.

The countries covered in the neuroendocrine tumors market report are South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and rest of Middle East and Africa.

Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2028 as Middle East and Africa counties are major developing countries and focus on increasing R&D activities in pharma and biotech sector and increase outsourcing services. South Africa is expected to dominate in the Middle East and Africa region due to technological advancements for the detection of neuroendocrine tumors.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rise in Government Initiatives and the Rising Collaborations by Market Players are creating new Opportunities in the Neuroendocrine Tumors Market

Neuroendocrine tumors market also provides you with detailed market analysis for every country growth in particular industry with neuroendocrine tumors sales, impact of advancement in the neuroendocrine tumors and changes in regulatory scenarios with their support for the neuroendocrine tumors market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Neuroendocrine Tumors Market Share Analysis

Neuroendocrine tumors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to neuroendocrine tumors market.

The major companies in neuroendocrine tumors market are Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., GlaxoSmithKline plc, Thermo Fisher Scientific Inc., Hutchison China MediTech Limited, F. Hoffmann-La Roche Ltd, Bionano Genomics, Teva Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Illumina, Inc., and LUPIN among others global or domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the neuroendocrine tumors market.

For instance,

  • In January 2018, Novartis AG had proclaimed that Advanced Accelerator Applications, a subsidiary of Novartis AG had received FDA approval for its new drug application Lutathera (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) including foregut, midgut and hindgut neuroendocrine tumors in adults. The FDA approval received by the company resulted in rise in clinical trials, enhanced oncology product portfolio in neurology and it would deliver a positive growth in the market.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the neuroendocrine tumors market which also provides the benefit for organisation to improve their offering for treatment.

Customization Available: Middle East and Africa Neuroendocrine Tumors Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, PIPELINE ANALYSIS

TABLE 2 SALES DATA OF ONCOLOGY MARKET FOR 2019/2020

TABLE 3 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2028(USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA NON-FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA FUNCTIONAL NET IN NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION 2019-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA GASTROINTESTINAL TRACT (GI) IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA LUNGS IN NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA PANCREAS NEUROENDOCRINE TUMORS MARKET, BY SITE 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA GRADE 2 (INTERMEDIATE-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA GRADE 3 (HIGH-GRADE TUMOR) IN NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA TREATMENT NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA LIVER-DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA HOSPITALS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA SPECIALITY CLINICS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA RADIATION CENTERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN RADIOTHERAPY MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA DIRECT TENDER IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA RETAIL SALES IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, COUNTRY, 2021-2028 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )

TABLE 44 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION

TABLE 48 MIDDLE EAST AND AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION , 2021-2028 (USD MILLION)

TABLE 56 MIDDLE EAST ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 58 MIDDLE EASTA AND AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 60 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION )

TABLE 61 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)

TABLE 62 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)

TABLE 63 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 64 SOUTH AFRICA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 65 SOUTH AFRICA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 66 SOUTH AFRICA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 67 SOUTH AFRICA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 68 SOUTH AFRICA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 69 SOUTH AFRICA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 70 SOUTH AFRICA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 71 SOUTH AFRICA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 72 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 73 SOUTH AFRICA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 74 SOUTH AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 75 SOUTH AFRICA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 76 SOUTH AFRICA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)

TABLE 78 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)

TABLE 79 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 81 SAUDI ARABIA DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 82 SAUDI ARABIA IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 83 SAUDI ARABIA TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 84 SAUDI ARABIA SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 85 SAUDI ARABIA TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 86 SAUDI ARABIA RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 87 SAUDI ARABIA SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 88 SAUDI ARABIA LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 89 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 90 SAUDI ARABIA ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 91 SAUDI ARABIA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 92 SAUDI ARABIA NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 93 SAUDI ARABIA PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 94 EGYPT EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)

TABLE 95 EGYPT NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)

TABLE 96 EGYPT NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)

TABLE 97 EGYPT NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 98 EGYPT DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 99 EGYPT IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 100 EGYPT TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 101 EGYPT SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 102 EGYPT TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 103 EGYPT RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 104 EGYPT SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 105 EGYPT LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 106 EGYPT NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 107 EGYPT ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 108 EGYPT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 109 EGYPT NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 110 EGYPT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 111 ISRAEL EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)

TABLE 112 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)

TABLE 113 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)

TABLE 114 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 115 ISRAEL DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 116 ISRAEL IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 117 ISRAEL TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 118 ISRAEL SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 119 ISRAEL TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 120 ISRAEL RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 121 ISRAEL SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 122 ISRAEL LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 123 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 124 ISRAEL ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 125 ISRAEL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 126 ISRAEL NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 127 ISRAEL PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 128 UAE EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)

TABLE 129 UAE NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)

TABLE 130 UAE NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)

TABLE 131 UAE NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 132 UAE DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 133 UAE IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 134 UAE TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 135 UAE SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 136 UAE TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 137 UAE RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 138 UAE SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 139 UAE LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 140 UAE NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 141 UAE ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 142 UAE PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 143 UAE NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 144 UAE PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 145 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)

TABLE 146 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY SITE, 2021-2028 (USD MILLION)

TABLE 147 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY GRADE, 2021-2028 (USD MILLION)

TABLE 148 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 149 KUWAIT DIAGNOSIS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 150 KUWAIT IMAGING TEST IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 151 KUWAIT TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 152 KUWAIT SOMATOSTATIN ANALOGS IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 153 KUWAIT TARGETED THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 154 KUWAIT RADIATION THERAPY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 155 KUWAIT SURGERY IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 156 KUWAIT LIVER DIRECTED TREATMENT IN NEUROENDOCRINE TUMORS MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 157 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 158 KUWAIT ORAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 159 KUWAIT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

TABLE 160 KUWAIT NEUROENDOCRINE TUMORS MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 161 KUWAIT PARENTERAL IN NEUROENDOCRINE TUMORS MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 162 REST OF MIDDLE EAST AND AFRICA EUROENDOCRINE TUMORS MARKET, BY CLASSIFICATION, 2021-2028 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions